Preference criteria for regorafenib in treating refractory metastatic colorectal cancer are the small tumor burden, slow growth and poor/scanty spread.
Hsu HC, Huang KC, Chen WS, Jiang JK, Yang SH, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, Huang SC, Cheng HH, Yang TS, Chen CC, Chao Y, Teng HW.
Hsu HC, et al. Among authors: chen cc, chen ws.
Sci Rep. 2021 Jul 28;11(1):15370. doi: 10.1038/s41598-021-94968-x.
Sci Rep. 2021.
PMID: 34321583
Free PMC article.
Clinical Trial.